Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

H1ssF-Grippeimpfstoff-Klinische Studie

16. September 2026 aktualisiert von: University of Minnesota

Klinische Studie des H1ssF-Impfstoffs im Vergleich zum saisonalen Influenza-Impfstoff bei zuvor ungeimpften Erwachsenen und zuvor geimpften Erwachsenen

This is a two-arm, open-label, randomized, phase 1, controlled clinical trial intended to evaluate the safety and immunologic response to the experimental vaccine H1ssF (H1 stabilized stem ferritin nanoparticle) and the seasonal flu vaccine Flucelvax.

Studienübersicht

Status

Zurückgezogen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Phase

  • Phase 1

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults aged 18-70 years inclusive.

  • Previous influenza immunization status:

    1. MN participants must have received at least 3 licensed seasonal flu vaccine doses over the past 5 years (fall or winter of 2021-2025).
    2. MN participants should have a gap of at least 6 months between their last seasonal flu vaccine and study enrollment.
    3. Uganda participants must have no prior exposure to any flu vaccine.
  • The participant is able and willing to provide informed consent.

  • Medical chart review and medical history without clinically significant findings or concerns.

  • Physical examination without clinically significant findings or concerns.

  • Body mass index (BMI) ≤ 30 kg/m2. This inclusion criterion can be voided if the participant is otherwise eligible and the study team finds the participant suitable for the LN biopsy via LN palpation on the physical exam.

  • Screening laboratory results (blood) within institutional normal ranges (unless specified below otherwise). Screening lab tests include: CBCD, comprehensive metabolic panel (i.e., AST, ALT, ALP, BUN, creatinine, glucose, Na, K, Ca, total protein, albumin, total bilirubin), and HIV Ag/Ab test. Acceptance of screening lab results outside of the ranges below will need to be accompanied by a site investigator's approval.

    1. Hb ≥ 11 g/dL (males) or ≥ 10.5 g/dL (females).
    2. White blood cell (WBC) count in the range of 4,000-11,000 cells/μL.
    3. Normal WBC differential per institutional ranges.
    4. Total lymphocyte count ≥ 800 cells/μL.
    5. Platelet count in the range of 125,000-500,000 cells/μL.
    6. Na = 135-145 mmol/L
    7. K = 3.4-5.3 mmol/L
    8. Creatinine = 0.67-1.28 mg/dL
    9. Blood urea nitrogen (BUN) ≤ 20 mg/dL
    10. Glucose (non-fasting) = 65-116 mg/dL
    11. Ca = 8.6-10.0 mg/dL
    12. Total protein ≥ 6.0 g/dL
    13. Albumin ≥ 3.5 g/dL
    14. Total bilirubin ≤ 1.2 mg/dL
    15. ALP ≤ 165 U/L
    16. AST ≤ 50 U/L
    17. ALT ≤ 87 U/L
    18. Negative for HIV infection per study testing (FDA approved method of detection): non-reactive licensed 4th generation (Ag/Ab) HIV rapid test, EIA, or CIA.
  • Women of reproductive potential / premenopausal:

    1. Negative beta-human chorionic gonadotropin (β-HCG) urine or serum pregnancy test at screening.

    2. Agrees to avoid pregnancy during the study.

    3. Agrees to use an effective means of birth control from at least 21 days prior to baseline visit through the end of the study (week 40). Acceptable birth control for this study is defined as:

      • Sexual abstinence with male partners.
      • Surgical sterilization (tubal ligation).
      • Male condom with or without a spermicidal agent.
      • Female condom.
      • Diaphragm or cervical cap.
      • Intrauterine device (IUD) (published data shows that expected failure rate is < 1% per year).
      • Hormone-based contraceptives including oral pills, injectables, implants, rings, and patches.
      • Partner has vasectomy.
  • The participant is agreeable to the following study requirements:

    1. The participant should not receive an off-study flu vaccine until they complete the study (40 weeks from enrollment).
    2. The participant is available and willing to attend research visits for 40 weeks after enrollment and undergo all study procedures to provide samples, which are to be used for research-only purposes and can be stored indefinitely.
    3. The participant is able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
    4. The participant should not receive any other investigational research agents until they complete the study.
    5. The participant does not foresee becoming ineligible during study participation.

Exclusion Criteria:

  • Breast-feeding or planning to become pregnant during the study.

  • Any of the following substances are exclusionary if currently used or planned to be used at any time during the 40-week study period:

    1. Systemic immunosuppressive medications within the 4 weeks prior to enrollment (e.g., corticosteroid therapy equal to or exceeding a dose of 15 mg/day of prednisone for more than 10 days, IL-2, interferon, methotrexate, cancer chemotherapy). Use of inhaled, nasal spray, or topical steroids is not exclusionary.
    2. Any cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment.
    3. Blood products within 16 weeks prior to enrollment.
    4. Live attenuated vaccines within 4 weeks prior to enrollment.
    5. Inactivated vaccines within 2 weeks prior to enrollment.
    6. Investigational research agents within 4 weeks prior to enrollment.
    7. Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule.
    8. Current anti-tuberculosis prophylaxis or therapy.
    9. Previous investigational influenza vaccines.
    10. Previous investigational ferritin-based vaccines.
  • History of any of the following clinically significant conditions:

    1. Severe allergic reactions to influenza vaccines in the past (e.g., Guillain-Barré syndrome, anaphylaxis, or angioedema)
    2. Other reactions to any vaccines that preclude receipt of the study vaccination as determined by the investigator.
    3. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.
    4. Asthma that requires prednisone therapy 3 or more times in a 12-month period or rescue inhaler therapy more than weekly.
    5. Diabetes mellitus (type I or II), except for gestational diabetes.
    6. Thyroid disease that is not well controlled.
    7. Idiopathic urticaria within the past year.
    8. Autoimmune disease or immunodeficiency.
    9. Hypertension that is not well controlled (baseline systolic > 140 mmHg or diastolic > 90 mmHg).
    10. Bleeding disorder diagnosed by a healthcare professional (e.g., factor deficiency, coagulopathy, or platelet disorder) or significant bruising or bleeding difficulties with IM injections or blood draws.
    11. Active malignancy requiring systemic chemotherapy or surgery within preceding 12 months or expected during study participation. Minor surgical removal of localized skin cancers (squamous cell carcinoma, basal cell carcinoma) is permitted.
    12. Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 12 months ago, or 3) seizures that have not required treatment within the last 12 months.
    13. Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen.
    14. Guillain-Barré Syndrome.
    15. Current/active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    16. Any medical, psychiatric, social condition, occupational reason, or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation, puts participant at risk, influences results of the study, or impairs a participant's ability to provide informed consent.
  • History of ≥3 previous inguinal LN biopsies.

  • Not a suitable surgical candidate per investigators' assessment.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: H1ssF-Impfstoff

Experimental influenza vaccine

Aktiver Komparator: Flucelvax Saisonimpfstoff

Licensed influenza vaccine

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Occurrence of solicited local reactogenicity for 7 days after vaccine administration
Zeitfenster: Day 7

Number of participants with solicited local symptoms per protocol

Day 7
Occurrence of solicited systemic reactogenicity for 7 days after vaccine administration
Zeitfenster: Day 7

Number of participants with solicited systemic symptoms per protocol

Day 7
Occurrence of adverse events of all severities from baseline through 1-week follow-up after the 2nd LN biopsy on week 4 study visit
Zeitfenster: Week 5

Number of participants with any adverse event through week 5

Week 5
Occurrence of serious adverse events at any time throughout the study
Zeitfenster: Week 40

Number of participants with any serious adverse event throughout the study

Week 40

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Binding antibody responses to H1ssF at week 2 after vaccination in both cohorts (US and Uganda)
Zeitfenster: Week 2

Antibody titer to H1ssF at week 2 after vaccination

Week 2
Binding antibody responses to the Flucelvax HAs at week 2 after vaccination in both cohorts (US and Uganda)
Zeitfenster: Week 2

Antibody titer to H1ssF at week 2 after vaccination

Week 2

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Tim Schacker, MD, University of Minnesota

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. August 2026

Primärer Abschluss (Geschätzt)

1. März 2028

Studienabschluss (Geschätzt)

1. März 2028

Studienanmeldedaten

Zuerst eingereicht

9. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. Januar 2026

Zuerst gepostet (Tatsächlich)

14. Januar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

21. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • IDIM-2025-31286

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .